title: [Pathogen reduction of blood components: from financial issues to possible long-term consequences].
abstract: Pathogen inactivation of blood products represents a global and major paradigm shift in transfusion medicine. In the next near future, it is likely that most blood products will be inactivated by various physicochemical approaches. The concept of blood safety will be challenged as well as transfusion medicine practice, notably for donor selection or biological qualification. In this context, it seems mandatory to develop analytical economic approaches by assessing costs-benefits ratio of blood transfusion as well as to set up cohorts of patients based on hemovigilance networks allowing rigorous scientific analysis of the benefits and the risks of blood transfusion at short- and long-term.
authors: Service régional vaudois de transfusion sanguine, Épalinges, Suisse.
authors: G
authors: G
authors: Canellini
authors: J-B
authors: JB
authors: Wasserfallen
authors: J-D
authors: JD
authors: Tissot
mesh_terms: D016913:Blood Component Transfusion / Q000009:adverse effects*; D017848:Blood-Borne Pathogens; D006801:Humans; D017053:Infection Control / Q000191:economics* / Q000379:methods*